Murdock Hunter R. 4
4 · Axsome Therapeutics, Inc. · Filed Jun 23, 2025
Insider Transaction Report
Form 4
Murdock Hunter R.
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2025-06-20$29.91/sh+7,500$224,325→ 7,500 total - Exercise/Conversion
Common Stock
2025-06-23$29.91/sh+6,014$179,879→ 6,014 total - Sale
Common Stock
2025-06-20$102.47/sh−7,500$768,525→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-20−7,500→ 22,383 totalExercise: $29.91From: 2023-03-04Exp: 2032-03-04→ Common Stock (7,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-23−6,014→ 16,369 totalExercise: $29.91From: 2023-03-04Exp: 2032-03-04→ Common Stock (6,014 underlying) - Sale
Common Stock
2025-06-23$100.12/sh−6,014$602,122→ 0 total
Footnotes (4)
- [F1]Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
- [F2]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F3]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $101.84 and $103.07
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $100.67.